Compare DLPN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | CANF |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 4.7M |
| IPO Year | 2008 | 2011 |
| Metric | DLPN | CANF |
|---|---|---|
| Price | $1.52 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 9.5K | ★ 614.9K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,699,389.00 | N/A |
| Revenue This Year | $14.73 | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $0.75 | $0.17 |
| 52 Week High | $1.88 | $10.40 |
| Indicator | DLPN | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 37.08 |
| Support Level | $1.46 | $0.59 |
| Resistance Level | $1.74 | $4.74 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 26.92 | 15.66 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.